Appendix 4E and 2026 Annual Report
Filed with ASX · · 64 pages · English
Summary by 6ix AI
The report indicates a significant increase in income from ordinary activities, while the loss attributable to owners has decreased compared to the previous year. The filing also highlights the company's strategic focus on expanding its clinical evidence and intellectual property portfolio.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Entropy Neurodynamics Limited on 6ix
In the deck
Story so far
Earlier from Entropy Neurodynamics
- Entropy Advances TRP-8803 to US Phase 2 in Depression
- TRP 8803 manufacturing secured for Phase 2/3 advancement
- 72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
- 72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
- South Africa Grants ENP Broad Fibromyalgia Patent to 2043
Later from Entropy Neurodynamics
- All Patients Improve, 50% Achieve 12-Week BED Remission
- TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
- Quarterly Activities Report and Appendix 4C
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics